Quintrio
Home

PHARMACEUTICAL PREPARATIONS

GRI Bio, Inc. Common Stock

GRI

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.39 – $1.53
Volume 22,127
Market cap $3M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.06M
Price / earnings
—
Price / book
0.35×
Price / sales
—
EV / sales
—
EV / EBITDA
0.82×

Profitability

Earnings per share
-$3.57
Return on assets
-79.98%
Return on equity
-88.63%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
10.21×
Quick ratio
10.21×
Cash ratio
9.94×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.58M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GRI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.3M$1.24M$1.64M$1.03M$1.6M$1.02M$1.41M$1.05M
Research and development$212K$407K$361K$1.63M$1.77M$1.88M$1.64M$907K
Total operating expenses$1.51M$1.65M$2M$2.66M$3.37M$2.9M$3.05M$1.95M
Operating income-$1.51M-$1.65M-$2M-$2.66M-$3.37M-$2.9M-$3.05M-$1.95M
Interest expense$5K$5K$5K$0$6K$5K$5K$0
Income before taxes-$1.51M-$1.64M-$2M-$2.66M-$3.36M-$2.89M-$3.05M-$1.95M
Income taxes$0$0$0$0$0$0$0$0
Net income-$1.51M-$1.64M-$2M-$2.66M-$3.36M-$2.89M-$3.05M-$1.95M
Net income attributable to common shareholders-$1.51M-$1.64M-$2M-$2.66M-$3.36M-$2.89M-$3.05M-$3.86M
EBITDA-$1.51M-$1.65M-$2M-$2.66M-$3.36M-$2.9M-$3.05M-$1.95M
Basic earnings per share-$0.69-$0.91-$1.61—-$35.88-$36.72-$162.30-$1.97
Diluted earnings per share-$0.69-$0.91-$1.61—-$35.88-$36.72-$162.30-$1.97

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

Windtree Therapeutics, a biotechnology company, announced the appointment of Leanne Kelly to its board of directors. Ms. Kelly has significant public company executive experience and will serve as an independent director and chair of the audit committee.

GlobeNewswire Inc.

GRI Bio Announces Exercise of Warrants

GRI Bio, a biotechnology company, announced the exercise of existing warrants and the issuance of new warrants. The company intends to use the proceeds for working capital and general corporate purposes.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Dec 19, 2019$22,147.0376Dec 27, 2019recurring
Sep 19, 2019$11,716.1117Sep 26, 2019recurring
Jun 20, 2019$16,137.3758Jun 27, 2019recurring
Mar 21, 2019$15,005.9619Mar 28, 2019recurring
Dec 20, 2018$17,733.5704Dec 27, 2018recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 26, 20261-for-28reverse split
Feb 24, 20251-for-17reverse split
Jun 18, 20241-for-13reverse split
Jan 30, 20241-for-7reverse split